MENU
Showcases Stock ranks Forex

Avidity Biosciences Inc (RNA)
19.54  0.55 (2.9%) 08-08 16:00
Open: 19.74 Pre. Close: 18.99
High: 20.25 Low: 18.94
Volume: 243,372 Market Cap: 972M
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 20.262 - 20.322 20.322 - 20.389
Low: 18.765 - 18.835 18.835 - 18.914
Close: 19.414 - 19.522 19.522 - 19.643
Stock Technical Analysis
Overall:     
Target: Six months: 23.65
One year: 27.63
Support: Support1: 17.17
Support2: 15.26
Resistance: Resistance1: 20.25
Resistance2: 23.65
Pivot: 17.42
Moving Averages: MA(5): 18.18
MA(20): 17.42
MA(100): 15.77
MA(250): 18.89
MACD: MACD(12,26): 0.70
Signal(12,26,9): 0.56
%K %D: %K(14,3): 84.42
%D(3): 70.63
RSI: RSI(14): 65.51
52-Week: High: 29.25
Low: 10.89
Change(%): 7.6
Average Vol(K): 3-Month: 377
10-Days: 291
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ RNA ] has closed below upper band by 1.2%. Bollinger Bands are 2.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Fri, 05 Aug 2022
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Tue, 02 Aug 2022
Avidity Biosciences Enrolls Patients in the MARINAâ„¢ Open-Label Extension Study - Yahoo Finance

Mon, 01 Aug 2022
Avidity Biosciences, Inc. (RNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Nasdaq

Mon, 25 Jul 2022
DekaBank Deutsche Girozentrale Buys 1400 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World

Wed, 20 Jul 2022
Shareholders in Avidity Biosciences (NASDAQ:RNA) are in the red if they invested a year ago - Yahoo Movies UK

Tue, 19 Jul 2022
Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank - Defense World

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 49.76
% Held by Insiders 38610000.00
% Held by Institutions 7.23
Shares Short (K) 4930
Shares Short Prior Month (K)
Stock Financials
EPS -127810000.000
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm) 528.5
Return on Equity (ttm) -21.9
Qtrly Rev. Growth 8420000.0
Gross Profit (p.s.) -30.545
Sales Per Share -35.273
EBITDA (p.s.) -83509088.000
Qtrly Earnings Growth -2.91
Operating Cash Flow (M)
Levered Free Cash Flow (M) -104.71
Stock Valuation
PE Ratio
PEG Ratio
Price to Book value
Price to Sales -0.55
Price to Cash Flow 2.82
Stock Dividends
Dividend
Dividend Yield
Dividend Growth 5900000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android